# SUPPLEMENTARY MATERIAL

**Table S1**. Websites of the natural product databases of Latin America.

| **Database name** | **Country** | **Database website** |
|---|---|---|
| NaturAr | Argentina | https://naturar.quimica.unlp.edu.ar/es/ |
| NuBBE$_{DB}$ | Brazil | http://nubbe.iq.unesp.br/portal/nubbe-search.html |
| SistematX | Brazil | https://sistematx.ufpb.br/ |
| UEFS | Brazil | http://zinc12.docking.org/catalogs/uefsnp |
| NAPRORE-CR | Costa Rica | * |
| LAIPNUDELSAV | El Salvador | * |
| UNIIQUIM | Mexico | https://uniiquim.iquimica.unam.mx/ |
| BIOFACQUIM | Mexico | Database version 2 https://figshare.com/articles/dataset/BIOFACQUIM_V2_sdf/11312702 |
| CIFPMA | Panama | * |
| PeruNPDB | Peru | https://perunpdb.com.pe/ |

*No available.

**Table S2**. Rules of thumb - guides - associated with drug-likeness.

| | Molecular weight | LogP | Number of hydrogen bond acceptors | Number of hydrogen bond donors | Sum of hydrogen bond acceptors and donors | Topological polar surface area | Number of rotatable bonds | References |
|---|---|---|---|---|---|---|---|---|
| Lipinski's rule of 5 | ≤ 500 | ≤ 5 | ≤ 10 | ≤ 5 | | | | [1,2] |
| Veber's rules | | | | | ≤ 12 | ≤ 140 | ≤ 10 | [3] |
| GlaxoSmithKline's 4/400 rule | <400 | <4 | | | | | | [4] |
| Pfizer 3/75 rule | | >3 | | | | < 75 | | [5] |

**Table S3**. Analysis metrics of the principal component analysis.

| Descriptors | LaNaPDB, COCONUT and approved drugs comparison | | Latin American countries comparison | |
|---|---|---|---|---|
| | PC1* | PC2** | PC1 | PC2 |
| SlogP | 0.14028102 | -0.79233759 | 0.23778911 | -0.67762065 |
| Topological polar surface area | -0.4891108 | 0.11257005 | -0.51947212 | 0.08670239 |
| Molecular weight | -0.45033318 | -0.27365197 | -0.42878314 | -0.37683651 |
| Number of rotatable bonds | -0.31703665 | -0.50279962 | -0.24992425 | -0.58680117 |
| Number of hydrogen bond donors | -0.4633437 | 0.14429034 | -0.41631399 | 0.21532234 |
| Number of hydrogen bond acceptors | -0.47232644 | 0.10495983 | -0.50395496 | 0.02465498 |
| Explained variance percentage | 67.1% | 22.2% | 59.8% | 24.8% |
| Sum of PC1 and PC2 explained variance percentage | 89.3% | | 84.6% | |

*Principal component 1; **Principal component 2

## References


1. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.* **2001**, *46*, 3–26, doi:10.1016/S0169-409X(00)00129-0.

2. Lipinski, C.A. Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discov. Today Technol.* **2004**, *1*, 337–341, doi:10.1016/j.ddtec.2004.11.007.

3. Veber, D.F.; Johnson, S.R.; Cheng, H.-Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. *J. Med. Chem.* **2002**, *45*, 2615–2623, doi:10.1021/jm020017n.

4. Gleeson, M.P. Generation of a set of simple, interpretable ADMET rules of thumb. *J. Med. Chem.* **2008**, *51*, 817–834, doi:10.1021/jm701122q.

5. Hughes, J.D.; Blagg, J.; Price, D.A.; Bailey, S.; Decrescenzo, G.A.; Devraj, R.V.; Ellsworth, E.; Fobian, Y.M.; Gibbs, M.E.; Gilles, R.W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4872–4875, doi:10.1016/j.bmcl.2008.07.071.